Top Story

VIDEO: EMBRACE-STEMI yields 'hypothesis-generating' results despite drug not meeting study endpoints

March 27, 2015

SAN DIEGO — In this video, C. Michael Gibson, MD, of Beth Israel Deaconess Medical Center, Harvard Medical School, outlines results from the EMBRACE-STEMI trial, which he presented at the American College of Cardiology Scientific Sessions.

The trial assessed the use of Bendavia (Stealth Biotherapeutics), a molecule intended to bind to and stabilize mitochondria, improving electron transport and energetics in cells, among patients with STEMI. Gibson noted that Bendavia reduced infarct size by 10% to 40% in animal studies, without increasing heart rate or BP.

Arshed Quyyumi, MD Meeting News Coverage

Autologous cell therapy continues to show benefit in patients with LV dysfunction after STEMI

March 27, 2015
SAN DIEGO — At 12-month follow-up, autologous CD34+ cell therapy for patients with left ventricular dysfunction after STEMI appears to be safe and may be…
In the Journals

New CVD risk score can be adjusted for use in any country

March 27, 2015
A new risk equation can be recalibrated for application in any country with routinely available information, researchers reported in The Lancet Diabetes &
Breaking News

Senate adjourns without voting on bill to repeal sustainable growth rate

March 27, 2015
The U.S. Senate left for its 2-week spring break without voting on a bill that repeals the sustainable growth rate, leaving physicians to face a 21% payment cut if…
Paul Sorajja, MD Meeting News CoveragePerspective

First report of US commercial data for transcatheter mitral valve repair system shows favorable outcomes

March 27, 2015
SAN DIEGO — In the first report of U.S. commercial experience with transcatheter mitral valve repair presented at American College of Cardiology Scientific…
More News Headlines »
CME
Obesity Consults: Volume 2, Number 2 Obesity Forum 2014 Highlights

Obesity Consults: Volume 2, Number 2
Obesity Forum 2014 Highlights

This activity is supported by educational grants from Takeda Pharmaceuticals International, Inc., US Region and Orexigen Therapeutics, Inc; Eisai, Inc.; Novo Nordisk; Vivus, Inc.

Management of obesity is complex, factoring in psychological, environmental, and physiologic causes. Treatment options…
More »
Meeting News Coverage Video
thumbnail for video 4136459899001

VIDEO: PEGASUS-TIMI 54 suggests benefit of long-term DAPT

March 26, 2015
SAN DIEGO — In this video, Deepak L. Bhatt, MD, MPH, Chief Medical Editor of Cardiology Today's Intervention…
More »
CME
Severe Hypertriglyceridemia: Confronting the Complex Issues in Etiology and Treatment

Severe Hypertriglyceridemia: Confronting the Complex Issues in Etiology and Treatment

This activity is supported by an educational grant from AstraZeneca.

Hypertriglyceridemia is a highly prevalent, yet modifiable, risk factor for atherosclerotic disease, pancreatitis, and…
More »
morganatic-roan